Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

              Author:Querol, Luis   Lewis, Richard   Hartung, Hans-Peter   Van Doorn, Pieter   Wallstroem, Erik   Luo, Xiaodong   Alonso Alonso, Miguel   Atassi, Nazem   Hughes, Richard   

              Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S15.008  

              Author Institution:Hospital de la Santa Creu i Sant Pau, Barcelona, Spain  Cedars Sinai Medical Center, Los Angeles, CA  Heinrich Heine University , Dusseldorf, Germany  Erasmus MC, University Medical Center, Rotterdam, Netherlands  Sanofi R&D, Neurology Development, Cambridge, MA  Sanofi R&D, Biostatistics and Programming, Bridgewater, NJ  UCL Queen Square Institute of Neurology, University College London, London, United Kingdom